TransMedics Group, Inc. (NASDAQ:TMDX) Holdings Lifted by Farther Finance Advisors LLC

Farther Finance Advisors LLC grew its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 187.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 485 shares of the company’s stock after buying an additional 316 shares during the period. Farther Finance Advisors LLC’s holdings in TransMedics Group were worth $76,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vaughan Nelson Investment Management L.P. bought a new stake in TransMedics Group during the 2nd quarter valued at $39,862,000. Driehaus Capital Management LLC lifted its holdings in TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the period. Hood River Capital Management LLC bought a new position in TransMedics Group in the 2nd quarter valued at about $18,854,000. Canada Pension Plan Investment Board bought a new position in TransMedics Group in the 2nd quarter valued at about $16,086,000. Finally, F M Investments LLC acquired a new position in TransMedics Group during the 2nd quarter valued at about $10,957,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of TMDX opened at $91.41 on Wednesday. The company has a 50-day moving average of $130.45 and a two-hundred day moving average of $139.89. The stock has a market cap of $3.07 billion, a price-to-earnings ratio of 101.04 and a beta of 2.08. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a one year low of $56.83 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same period in the prior year, the business posted ($0.12) EPS. The company’s revenue for the quarter was up 63.7% on a year-over-year basis. On average, equities research analysts expect that TransMedics Group, Inc. will post 1.07 earnings per share for the current year.

Insider Transactions at TransMedics Group

In related news, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,958 shares of company stock valued at $5,230,528 over the last quarter. Company insiders own 7.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on TMDX shares. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Needham & Company LLC decreased their price target on TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, October 29th. Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective on shares of TransMedics Group in a research note on Tuesday, October 29th. Oppenheimer decreased their target price on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Finally, JPMorgan Chase & Co. dropped their price target on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, TransMedics Group presently has an average rating of “Buy” and an average price target of $144.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.